Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells
Authors
Keywords
-
Journal
CELL BIOLOGY AND TOXICOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-14
DOI
10.1007/s10565-021-09640-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer
- (2020) Felix Meyer et al. Cells
- CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer
- (2020) Yinghui Zhou et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
- (2020) Chezi Ganzel et al. BRITISH JOURNAL OF HAEMATOLOGY
- DNA Damage Signaling-Induced Cancer Cell Reprogramming as a Driver of Tumor Relapse
- (2019) Doria Filipponi et al. MOLECULAR CELL
- Beta1 integrin blockade overcomes doxorubicin resistance in human T-cell acute lymphoblastic leukemia
- (2019) Sofiane Berrazouane et al. Cell Death & Disease
- An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication
- (2019) Tatiana N. Moiseeva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?
- (2019) Andrea Ghelli Luserna di Rorà et al. Journal of Hematology & Oncology
- Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells
- (2019) Makoto Takeuchi et al. Cancers
- APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells
- (2019) Casey D. Stefanski et al. NEOPLASIA
- Inhibition of novel GCN5-ATM axis restricts the onset of acquired drug resistance in leukemia
- (2018) Sameer Salunkhe et al. INTERNATIONAL JOURNAL OF CANCER
- The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
- (2018) Hye Jeong Park et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment
- (2018) Seung Woo Chung et al. BIOMATERIALS
- Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia
- (2018) Andrea Ghelli Luserna Di Rorà et al. Journal of Hematology & Oncology
- Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition
- (2017) Xiaoguang Wang et al. HAEMATOLOGICA
- The cell cycle checkpoint inhibitors in the treatment of leukemias
- (2017) A. Ghelli Luserna di Rora’ et al. Journal of Hematology & Oncology
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
- (2017) Andrew N. Blackford et al. MOLECULAR CELL
- Acute lymphoblastic leukemia: a comprehensive review and 2017 update
- (2017) T Terwilliger et al. Blood Cancer Journal
- Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition
- (2017) Xiaoguang Wang et al. HAEMATOLOGICA
- CHK1 as a therapeutic target to bypass chemoresistance in AML
- (2016) Laure David et al. Science Signaling
- Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
- (2016) Andrea Ghelli Luserna Di Rorà et al. Oncotarget
- CHK1 as a therapeutic target to bypass chemoresistance in AML
- (2016) Laure David et al. Science Signaling
- Imatinib inhibits inactivation of the ATM/ATR signaling pathway and recovery from adriamycin/doxorubicin-induced DNA damage checkpoint arrest
- (2015) Mariko Morii et al. CELL BIOLOGY INTERNATIONAL
- Chk1 and Wee1 control genotoxic-stress induced G2–M arrest in melanoma cells
- (2015) Julio Vera et al. CELLULAR SIGNALLING
- Mechanisms and Consequences of Double-Strand DNA Break Formation in Chromatin
- (2015) Wendy J. Cannan et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma
- (2015) Zuzanna Baranski et al. JOURNAL OF PATHOLOGY
- Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53
- (2015) Hyeon-Jun Shin et al. Scientific Reports
- Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma
- (2015) Meng-Tzu Weng et al. Scientific Reports
- Improved ataxia telangiectasia mutated kinase inhibitor KU60019 provides a promising treatment strategy for non-invasive breast cancer
- (2014) YING ZHU et al. Oncology Letters
- DNA-Damage Response during Mitosis Induces Whole-Chromosome Missegregation
- (2014) S. F. Bakhoum et al. Cancer Discovery
- Chromosome Preparation From Cultured Cells
- (2014) Bradley Howe et al. Jove-Journal of Visualized Experiments
- Doxorubicin, DNA torsion, and chromatin dynamics
- (2013) Fan Yang et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- FLAG-liposomal Doxorubicin (Myocet) Regimen for Refractory or Relapsed Acute Leukemia Pediatric Patients
- (2013) Paola Quarello et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer
- (2013) M. A. Batey et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic cytotoxic effects of inorganic phosphate and chemotherapeutic drugs on human osteosarcoma cells
- (2013) ANNAMARIA SPINA et al. ONCOLOGY REPORTS
- Elevated Cyclin G2 Expression Intersects with DNA Damage Checkpoint Signaling and Is Required for a Potent G2/M Checkpoint Arrest Response to Doxorubicin
- (2012) Maike Zimmermann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
- (2012) Marieke Aarts et al. Cancer Discovery
- MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts
- (2011) N. V. Rajeshkumar et al. CLINICAL CANCER RESEARCH
- MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
- (2011) K. A. Bridges et al. CLINICAL CANCER RESEARCH
- Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells
- (2011) David Davidson et al. INVESTIGATIONAL NEW DRUGS
- Thr-1989 Phosphorylation Is a Marker of Active Ataxia Telangiectasia-mutated and Rad3-related (ATR) Kinase
- (2011) Edward A. Nam et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study
- (2010) M. Hunault-Berger et al. HAEMATOLOGICA
- Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: results from an Australian population
- (2010) Kirk Morris et al. LEUKEMIA & LYMPHOMA
- Doxorubicin pathways
- (2010) Caroline F. Thorn et al. Pharmacogenetics and Genomics
- Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation
- (2010) Jay P. Reddy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells
- (2010) Regine Lüpertz et al. TOXICOLOGY
- Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
- (2009) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More